Tim Herbert: So when we were doing, when we went to Inspire 2, the procedure time went from approximately two hours down to 90 minutes on average. So in general, within the two incision, we were at 90 minutes. Now the top centers that have a high utilization, they have a lot of experience, they routinely run at about 60 minute procedure time today. So you can say the range of procedure time today with two incision is between 60 minutes and 90 minutes. When we go to Inspire 5, we will expect that to drop down to between 45 minutes and 60 minutes depending upon the experience of the surgeon. So it’s going to have both a benefit from implanting the sensing lead itself, but there also is improvement in our intraoperative testing.
What’s key to note here is remember that we do full operational testing in the operating room. So we know that the stimulation is moving the tongue forward and we know that we can review the respiratory signal. So we know we have a operational system before we close, and that’s we’re going to be able to improve that time when we go to Inspire 5 as well. And you had a follow up
Anthony Petrone: It was very helpful and maybe just a quick update on Phillips, we tuned into ResMed last week and Phillips reported also last week and there’s still just a lot of opaqueness around that process with FDA and SEC and DOJ. So, just any kind of updates on what you’re hearing around the Phillips recall? Thanks.
Tim Herbert: Yeah, I think, this has gone on for how many years now, and it’s just an ongoing frustration by everybody. And hopefully someday it’ll resolve. From our viewpoint, what it’s done is changed the paradigm for which sleep physicians look at treating sleep apnea and they no longer are dedicated just two CPAP. They’re opening up and saying, what other methods do we have out there that can treat our patients? And there’s a prospect of a new drug, right, that could possibly take care of milder cases. They still have CPAP, but now they have Inspire and they can for patients that don’t benefit from CPAP, they can quickly move on to Inspire. And we become part of the talk track earlier. And that really is going to be the long-term paradigm change that is going to be the benefit to the patients that they become aware of all the therapies earlier on in the process.
Operator: Thank you. And I show our next question comes from the line of Suraj Kalia from Oppenheimer and Co Inc. Please go ahead.
Suraj Kalia: Perfect. Congrats on a nice quarter. So Rick, one question for you and one question for Tim and I last both of them upfront. Rick, if I were to define new stores as one opened within the last 12 months, how would the new store, same store stale configuration look like in Q1? And Tim, forgive me, I got a little confused, so maybe you can help me here. So from a phenotype perspective, right, obese patients do have greater oropharyngeal collapse as a contributor to OSA and Hypoglossal nerve stem has been approved for high BMI. So is the notion now that a GNS cannot effectively target higher BMI or is it that first you got treated with GLP ones, let do the weight loss and then a GNS can be used in the high higher BMI category? Thank you for taking my questions.
